Showing 5281-5290 of 5621 results for "".
- Alkahest Presents Positive Phase 2a Study Results of AKST4290 for Treatment-Naïve Wet AMDhttps://modernod.com/news/alkahest-presents-positive-phase-2a-study-results-of-akst4290-for-treatment-naive-wet-amd/2476414/Alkahest shared results from its open label study, ALK4290-201. The data were delivered during a podium presentation as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress. The study evaluated the therapeutic effect an
- Novartis Plans for Alcon Spin-Off on April 9, 2019https://modernod.com/news/novartis-plans-for-alcon-spin-off-on-april-9-2019/2476408/Novartis confirmed that conditions needed for the 100% spin-off of the Alcon eye care business have been met, and the spinoff is expected to be completed on April 9, 2019. Each Novartis shareholder will receive 1 Alcon share for every 5 Novartis shares/American Deposit
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr
- Children’s Hospital Los Angeles Receives $1.6M Grant to Study Retinoblastomahttps://modernod.com/news/childrens-hospital-los-angeles-receives-1-6m-grant-to-study-retinoblastoma/2476397/Retinoblastoma is a tumor of the retina that generally affects children under 5 years of age and accounts for approximately 4% of childhood cancers. If not diagnosed early, retinoblastoma may result in loss of one or both eyes and can be fatal. David Cobrinik, MD, PhD, of The Saban Researc
- Optovue Launches New AngioWellness Scan at Vision Expo Easthttps://modernod.com/news/optovue-launches-new-angiowellness-scan-at-vision-expo-east/2476399/Optovue will launch its new AngioWellness scan at Vision Expo East in New York, March 21-24, 2019. The AngioWellness scan utilizes Optovue’s advanced AngioVue OCTA technology to quickly assess and diagnose new pathologies in patients, including diabetic patients and those who may be at ris
- 5% People Tested Positive at Free Initial Screenings for Glaucoma at Saifee Hospitalhttps://modernod.com/news/5-people-tested-positive-at-free-initial-screenings-for-glaucoma-at-saifee-hospital/2476400/Saifee Hospital, one of Mumbai’s leading multi-specialty hospitals, conducted almost 400 free eye check-ups for their visitors to observe World Glaucoma Week. The check-ups were conducted throughout the week and more than 20 people were detected to have high
- SynergEyes Launches Tangible Hydra-PEG Coating on SynergEyes VS Scleral Lenshttps://modernod.com/news/synergeyes-launches-tangible-hydra-peg-coating-on-synergeyes-vs-scleral-lens/2476394/SynergEyes announced that the SynergEyes VS scleral lens is now available with Tangible Hydra-PEG on Contamac material. The Tangible Hydra-PEG coating is designed to solve the problem of contact lens discomfort and dry eyes by minimizing deposits and lens fogging, increasing lens surface water re
- Nicox Initiates Phase 2 Trial of NCX 4251 in Blepharitishttps://modernod.com/news/nicox-initiates-phase-2-trial-of-ncx-4251-in-blepharitis/2476393/Nicox SA announced the initiation of a phase 2 clinical trial evaluating NCX 4251, its novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the first targeted topical treatm